clinical trial · NCT07306949
Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers
Alexion Pharmaceuticals, Inc.·phase4·recruiting·n = 200
Transthyretin-type Cardiac AmyloidosisAcoramidis
brief summary
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
started
Oct 1, 2025
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Jan 7, 2026
official title
A Multicenter, Open-Label, Single Arm, Post-Marketing Clinical Study to Evaluate the Therapeutic Effects of Acoramidis Hydrochlorideon Cardiac Biomarkers and Current Clinical Features in Patients With Transthyretin-type Cardiac Amyloidosis: The CARE ATTR Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol